Is it safe to co‑administer naproxen (NSAID) with cyclobenzaprine (muscle relaxant) for short‑term musculoskeletal pain?

Can Naproxen and Cyclobenzaprine Be Taken Together?

Yes, naproxen and cyclobenzaprine can be safely co-administered for short-term treatment of acute musculoskeletal pain, though the combination increases drowsiness without providing superior pain relief compared to naproxen alone. 1, 2

Safety Profile of the Combination

• The FDA drug label explicitly states that concomitant administration of cyclobenzaprine and naproxen was well tolerated with no unexpected adverse effects reported in clinical studies. 1

• The primary concern with combining these medications is increased drowsiness—combination therapy produces more sedation than naproxen monotherapy, but this is the expected additive effect of cyclobenzaprine's central nervous system properties. 1, 2

• No dangerous drug interactions exist between naproxen and cyclobenzaprine; naproxen does not significantly alter cyclobenzaprine plasma levels or bioavailability. 1

Evidence on Clinical Efficacy

• A randomized trial by Friedman et al. demonstrated that naproxen combined with cyclobenzaprine was effective for acute low back pain, though the CDC guideline citing this study notes it as part of evidence supporting non-opioid approaches. 3

• An open-label trial of 40 patients showed that cyclobenzaprine plus naproxen resulted in less objective muscle spasm, reduced tenderness, and greater range of motion compared to naproxen alone (P < 0.05), though this came at the cost of more drowsiness. 2

• However, a larger randomized community-based trial of 867 patients found that cyclobenzaprine 5 mg three times daily combined with ibuprofen (a similar NSAID to naproxen) was not superior to cyclobenzaprine monotherapy for acute neck or back pain with muscle spasm. 4

Practical Prescribing Guidance

• Limit treatment duration to 7–14 days maximum—all clinical trials of skeletal muscle relaxants were 2 weeks or less in duration, and prolonged use increases central nervous system adverse events (relative risk 2.04) without demonstrated benefit. 5, 6

• Start cyclobenzaprine at 5 mg three times daily rather than 10 mg to minimize sedation while maintaining efficacy—the 5 mg dose is as effective as 10 mg but better tolerated. 7

• Warn patients explicitly about drowsiness and advise against driving or operating machinery, especially during the first 3–4 days of combination therapy when sedation is most pronounced. 1, 2

• Consider using naproxen 500 mg twice daily as monotherapy first; add cyclobenzaprine only if muscle spasm is prominent and not adequately controlled, since the combination may not provide additional pain relief beyond the NSAID alone. 4

Important Clinical Caveats

• Avoid this combination in elderly patients (≥65 years)—cyclobenzaprine plasma concentrations are approximately 1.7-fold higher in the elderly, with elderly males showing 2.4-fold increases, substantially raising the risk of falls, confusion, and anticholinergic effects. 1

• Do not use in patients with hepatic impairment—both cyclobenzaprine AUC and Cmax approximately double in hepatic dysfunction; if combination therapy is essential, start cyclobenzaprine at 5 mg and titrate slowly. 1

• Monitor for gastrointestinal bleeding risk factors before prescribing naproxen—advanced age (≥60 years), history of peptic ulcer disease, concurrent corticosteroid or anticoagulant use, and untreated H. pylori infection all increase bleeding risk. 3

• Consider adding a proton pump inhibitor for gastroprotection if the patient has any gastrointestinal risk factors, as NSAIDs like naproxen can cause upper gastrointestinal bleeding and perforation. 3

• Be aware that naproxen may reduce renal elimination of other medications, though this interaction is not clinically significant with cyclobenzaprine specifically. 3, 8

When to Avoid the Combination

• Do not prescribe if the patient is taking monoamine oxidase inhibitors—cyclobenzaprine can precipitate serotonin syndrome in this setting. 6

• Avoid in patients with myasthenia gravis, urinary retention, angle-closure glaucoma, or recent myocardial infarction due to cyclobenzaprine's anticholinergic and cardiac effects. 6, 1

• Do not use in patients on therapeutic anticoagulation (warfarin, heparin)—oral NSAIDs significantly increase bleeding risk; consider topical NSAIDs instead if muscle relaxation is needed. 3